HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Polymorphisms in peptidylarginine deiminase associate with rheumatoid arthritis in diverse Asian populations: evidence from MyEIRA study and meta-analysis.

AbstractINTRODUCTION:
The majority of our knowledge regarding disease-related mechanisms of uncontrolled citrullination and anti-citrullinated protein antibody development in rheumatoid arthritis (RA) was investigated in Caucasian populations. However, peptidylarginine deiminase (PADI) type 4 gene polymorphisms are associated with RA in East Asian populations and weak or no association was found in Caucasian populations. This study explores the association between the PADI4 polymorphisms and RA risk in a multiethnic population residing in South East Asia with the goal of elucidating generalizability of association in non-Caucasian populations.
METHODS:
A total of 320 SNPs from the PADI locus (including PADI1, PADI2, PADI3, PADI4 and PADI6 genes) were genotyped in 1,238 RA cases and 1,571 control subjects from the Malaysian Epidemiological Investigation of Rheumatoid Arthritis (MyEIRA) case-control study. Additionally, we conducted meta-analysis of our data together with the previously published studies of RA from East Asian populations.
RESULTS:
The overall odds ratio (ORoverall) for the PADI4 (rs2240340) allelic model was 1.11 (95% confidence interval (CI) = 1.00 to 1.23, P = 0.04) and for the genotypic model was 1.20 (95% CI = 1.01 to 1.44, P = 0.04). Haplotype analysis for four selected PADI4 SNPs revealed a significant association of one with susceptibility (P = 0.001) and of another with a protective effect (P = 0.02). The RA susceptibility was further confirmed when combined meta-analysis was performed using these data together with data from five previously published studies from Asia comprising 5,192 RA cases and 4,317 control subjects (ORoverall = 1.23 (95% CI = 1.16 to 1.31, Pheterogeneity = 0.08) and 1.31 (95% CI = 1.20 to 1.44, Pheterogeneity = 0.32) in allele and genotype-based models, respectively). In addition, we also detected a novel association of PADI2 genetic variant rs1005753 with RA (ORoverall = 0.87 (95% CI = 0.77 to 0.99)).
CONCLUSION:
Our study demonstrates an association between PADI4 and RA in the multiethnic population from South East Asia and suggests additional association with a PADI2 gene. The study thus provides further support for the notion that polymorphisms in genes for enzymes responsible for citrullination contribute to RA development in multiple populations of Asian descent.
AuthorsChun Lai Too, Shahnaz Murad, Jasbir Singh Dhaliwal, Per Larsson, Xia Jiang, Bo Ding, Lars Alfredsson, Lars Klareskog, Leonid Padyukov
JournalArthritis research & therapy (Arthritis Res Ther) Vol. 14 Issue 6 Pg. R250 (Nov 19 2012) ISSN: 1478-6362 [Electronic] England
PMID23164236 (Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't)
Chemical References
  • Autoantibodies
  • Hydrolases
  • PADI2 protein, human
  • PADI4 protein, human
  • Protein-Arginine Deiminase Type 2
  • Protein-Arginine Deiminase Type 4
  • Protein-Arginine Deiminases
Topics
  • Adult
  • Arthritis, Rheumatoid (ethnology, genetics, immunology)
  • Asian People (genetics)
  • Autoantibodies (immunology)
  • Case-Control Studies
  • China
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Gene Frequency
  • Genetic Predisposition to Disease (ethnology, genetics)
  • Genotype
  • Haplotypes
  • Humans
  • Hydrolases (genetics)
  • Malaysia
  • Male
  • Middle Aged
  • Polymorphism, Single Nucleotide
  • Protein-Arginine Deiminase Type 2
  • Protein-Arginine Deiminase Type 4
  • Protein-Arginine Deiminases

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: